Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta director Martin Madaus received 5,663 restricted stock units on February 5, 2026 under the company’s 2020 Equity Incentive Plan. Each unit represents one share of Azenta common stock and was granted at no cost to him.
The units are fully vested on grant, but Madaus elected to defer settlement until the later of reaching age 65 or leaving the company. Following this award, he beneficially owns 9,703 derivative securities in the form of restricted stock units held directly.
Azenta director Dipal Doshi reported a stock grant from the company. On February 5, 2026, Doshi received 5,663 shares of Azenta common stock as a grant of unrestricted shares under the Company’s 2020 Equity Incentive Plan at a reported price of $27.85 per share. No cash was paid for this award, and Doshi now directly owns 9,703 common shares following the transaction.
Azenta, Inc. director Frank Casal reported receiving a grant of 7,243 shares of Azenta common stock on February 5, 2026 under the company’s 2020 Equity Incentive Plan. According to the filing, no cash was paid for this unrestricted share award.
After this grant, Casal beneficially owns 21,803 Azenta common shares, held directly. The transaction is reported as an acquisition of non-derivative securities and reflects routine equity-based compensation for a board member.
Azenta, Inc. director Erica McLaughlin received a grant of 5,663 shares of Azenta common stock on February 5, 2026. The shares are unrestricted and were granted under the company’s 2020 Equity Incentive Plan, with no cash paid for the grant. Following this award, she directly holds 22,521 Azenta common shares.
Azenta, Inc. director Robyn C. Davis received a grant of 5,663 restricted stock units on Azenta common stock on February 5, 2026. Each unit represents one share of common stock and was granted at a price of $0. The units are fully vested upon grant.
Davis elected to defer settlement of these units until the later of reaching age 65 or separating from service with the company. After this award, Davis beneficially owns 23,662 derivative securities in the form of restricted stock units, granted under Azenta’s 2020 Equity Incentive Plan.
Azenta, Inc. reported a net loss of $15.4M for the quarter ended December 31, 2025, compared with a loss of $11.0M a year earlier. Total revenue from continuing operations was broadly flat at $148.6M, with Sample Management Solutions at $81.4M and Multiomics at $67.2M.
Continuing operations generated a loss of $5.2M, while discontinued operations, mainly the B Medical Systems business, added a further loss of $10.2M. Azenta recorded a $9.7M loss on assets held for sale as it moves toward divesting B Medical.
Under a Share Purchase Agreement signed with Thelema S.À R.L., B Medical Systems is being sold for $63.0M. Thelema has paid a $9.0M deposit, with the remaining $54.0M due on or before March 31, 2026, subject to Thelema obtaining final financing; if this fails, Azenta retains $5.0M as a break-up fee.
Azenta ended the quarter with $336.6M in cash and cash equivalents, plus $228.9M in marketable securities, and total assets of $2.07B against liabilities of $359.6M. The company continues its 2024 restructuring program and has a new $250M share repurchase authorization through December 31, 2028, with no buybacks yet executed.
Azenta, Inc. announced its financial results for the fiscal quarter ended December 31, 2025 through a press release dated February 4, 2026. The company furnished this release as Exhibit 99.1, rather than treating it as formally filed for liability purposes. The disclosure also highlights that the release contains forward-looking statements and directs readers to the cautionary note in the press release for a discussion of related risks and uncertainties.
Azenta, Inc. reported that Alan P. Malus resigned from its Board of Directors, effective January 29, 2026. He also stepped down from his role on the Human Resources and Compensation Committee.
The company stated that his resignation was not due to any disagreement over operations, policies, or practices. Instead, he accepted full-time responsibilities with another company, which will limit the time he can devote to Azenta board duties.
Azenta, Inc. held its Annual Meeting of stockholders on January 28, 2026, where investors approved several key proposals. Stockholders elected all nominated directors to the board, with each nominee receiving a substantial majority of votes cast.
Stockholders approved, on a non-binding advisory basis, the overall compensation of Azenta’s named executive officers. They also approved an amendment to the Company’s 2020 Equity Incentive Plan to increase the number of shares reserved for issuance by 2,750,000, expanding the pool available for future equity awards. In addition, stockholders ratified the appointment of PricewaterhouseCoopers LLP as Azenta’s independent registered public accounting firm for the 2026 fiscal year.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting beneficial ownership of 2,099,441 Azenta Inc common shares, representing 4.6% of the outstanding class as of the reported date. Dimensional has sole power to vote 2,061,526 shares and sole power to dispose of 2,099,441 shares.
The shares are held across various funds and accounts for which Dimensional or its subsidiaries act as adviser or manager, and all securities are owned by those funds rather than by Dimensional itself. Dimensional states that the holdings are maintained in the ordinary course of business and are not intended to change or influence control of Azenta.